OLD Mission Capital LLC Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

OLD Mission Capital LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 21,347 shares of the medical equipment provider’s stock, valued at approximately $1,539,000.

A number of other hedge funds have also modified their holdings of the business. General Partner Inc. purchased a new stake in Hologic in the 4th quarter valued at about $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Raymond James restated an “outperform” rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Citigroup reduced their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Down 1.3 %

Shares of NASDAQ HOLX opened at $60.56 on Thursday. The business has a 50-day moving average of $64.69 and a two-hundred day moving average of $72.88. The company has a market capitalization of $13.59 billion, a price-to-earnings ratio of 19.10, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1 year low of $59.53 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.